AU ZH, Switzerland, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris”), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), today announced they have entered a collaboration agreement under which Araris will use its proprietary linker-conjugation platform to generate novel ADCs against undisclosed targets provided by Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma company with a focus on oncology.

AU ZH，瑞士，2023年11月8日（GLOBE NEWSWIRE）-Araris Biotech AG（“Araris”），一家开发下一代抗体-药物偶联物（ADC）的瑞士肿瘤生物技术公司，今天宣布他们已签订合作协议，Araris将使用其专有的连接子结合平台为日本研发驱动的专业制药公司Taiho Pharmaceutical Co.，Ltd。提供的未公开目标生成新型ADC，重点关注肿瘤学。

ADCs delivered by Araris will be further tested and evaluated by Taiho. The financial terms of the collaboration agreement were not disclosed. “We are proud to enter a collaboration with Taiho Pharmaceutical and look forward to working with the Taiho team to develop next-generation ADCs with improved efficacy and tolerability,” said Dragan Grabulovski, Ph.D., acting chief executive officer of Araris.

Araris提供的ADC将由Taiho进一步测试和评估。没有披露合作协议的财务条款。Araris代理首席执行官Dragan Grabulovski博士说：“我们很自豪与Taiho Pharmaceutical合作，并期待与Taiho团队合作开发具有更高功效和耐受性的下一代ADC。”。

Philipp Spycher, Ph.D., chief scientific officer of Araris added, “This agreement underlines the potential of our linker-payload platform to deliver novel ADCs with excellent properties, and it positions our company as a highly attractive partner for pharmaceutical companies.” About Araris Biotech AG Araris Biotech is a pioneering leader in the development of antibody-drug conjugates (ADCs) with the potential for unparalleled efficacy and tolerability.

Araris首席科学官Philipp Spycher博士补充说：“该协议强调了我们的连接器有效载荷平台提供具有优异性能的新型ADC的潜力，并将我们公司定位为制药公司极具吸引力的合作伙伴。“关于Araris Biotech AG Araris Biotech是抗体-药物偶联物（ADC）开发的开拓性领导者，具有无与伦比的功效和耐受性。

With a strong commitment to transforming the landscape of ADCs, Araris leverages its proprietary, ready-to-use linker-payload platforms and site-specific conjugation techniques to create a new frontier in targeted therapeutics. The company’s innovative approach ensures that ADCs are generated to be highly efficacious and tolerable as exemplified in a number of experiments using its topoisomerase- and auristatin- based linker-payloads, providing patients wi.

Araris致力于改变ADC的格局，利用其专有的，即用型的连接器有效载荷平台和特定于站点的共轭技术，在靶向治疗领域创造新的前沿。该公司的创新方法确保ADC的生成具有高效性和耐受性，如许多使用其拓扑异构酶和基于auristatin的接头有效载荷的实验所示，为患者提供wi。